Abstract:Objective To investigate the performance of DWI in the prediction of the response of gastrointestinal stromal tumor (GIST) to targeted therapy.Methods Twenty nine consecutive patients with unresectable GIST confirmed by pathology were enrolled in this prospective study.All patients were treated by imatinib mesylate single drug,and had at least one targeted lesion with longest diameter＞ 1 cm.MRI examinations were performed prior to and 2 weeks and 3 months afollowing treatment.The ADC of the whole lesion (ADCentire) and obviously high signal area on DWI (ADCmin) and the longest diameter (LD) on T2WIs were measured.The early percentage changes of the quantitative indicators (％ Δ LD,％ Δ ADCmin and ％ ΔADCentire) were calculated.All patients were divided into good response (GoodR) and poor response (PoorR) groups according to the combined response assessment criteria.The pre-therapy values and early percentage changes (％Δ) of the above quantitative parameters were compared using t test or Mann-Whitney U test.Receiver operating characteristic (ROC) curves were employed to compare the performance of the above quantitative parameters in the discrimination of response groups.Results A total of 82 lesions in 29 patients were included in the study.There were 57 lesions of GoodR and 25 lesions of PoorR.The pre-therapy baseline ADCmin and ADC in GoodR group were both lower than PoorR group [ADCmin:(0.90± 0.27) × 10-3 mm2/s vs.(1.15± 0.29) × 10-3 mm2/s,t=3.673,P＜0.01 ;ADCentire:(1.06 ± 0.26) × 10-3mm2/s vs.(1.31 ± 0.32) × 103mm2/s,t=3.698,P＜0.01].No statistical difference in baseline LD was displayed (P＞0.05).The ％ ΔADC ％ΔADC and ％ΔLD all had statistical difference between GoodR and PoorR groups(％ΔADCmin:48％ vs.3％,Z=-5.310,P＜0.01;％ΔADCentire:45％ vs.2％,Z=-5.768,P＜0.01;％ΔLD:-6％ vs.-1％,Z=-2.752,P＜0.01).Through ROC curves,the AUCs for pre-therapy ADCmin,ADCentire and LD were 0.735,0.721 and 0.503,respectively; and AUCs for ％ΔADCmin,％ΔADCentire and ％ΔLD after two weeks of therapy were 0.859,0.877 and 0.694,respectively,in the differentiation of responses.Using ％ ΔADCmin ≥ 13％ to predict GoodR,the sensitivity was 0.842 and specificity 0.760; Using ％ΔADCentire ≥ 22％ to predict GoodR,the sensitivity was 0.862 and specificity 0.800.Conclusions The percentage changes of the ADC after two weeks of therapy outperform the longest diameter and pre-therapy baseline ADC in the response predictionof GIST to targeted therapy.It is more effective of ADCentire than ADCmin values in the respo nse prediction.

Imaging Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumor

Examination Standards and Radiological Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumors

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Evaluation of therapeutic effect of tumor-targeted therapy.

Evaluation of Therapeutic Effect of Tumor-Targeted Therapy

Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs)

[Advances in radiological studies of gastrointestinal stromal tumors].

Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy:Current Status and Prospect

MR diffusion weighted imaging in the prediction of the response of unresectable gastrointestinal stromal tumor to targeted therapy

Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor Using CT Imaging

Preoperative radiological evaluation of the gastrointestinal stromal tumors

[Association of CT Image Changes and Prognosis in Gastrointestinal Stromal Tumor after Targeted Therapy].

[Radiological Evaluation on the Efficacy of Neoadjuvant Therapy for Gastrointestinal Tumors].

Diagnostic Methods for Initial Evaluation of Primary Gastrointestinal Stromal Tumors.

The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation

MRI in Predicting the Response of Gastrointestinal Stromal Tumor to Targeted Therapy: a Patient-Based Multi-Parameter Study

Imaging Diagnostic Value in Gastrointestinal Stromal Tumors

Building CT Radiomics-Based Models for Preoperatively Predicting Malignant Potential and Mitotic Count of Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients.

CT Features Combined with RECIST 1.1 Criteria Improve Progression Assessments of Sunitinib-Treated Gastrointestinal Stromal Tumors.

The strategy of surgical treatment and targeted therapy in gastrointestinal stromal tumors